Frequency Therapeutics Announces Positive Phase 1/2 Data for Drug Candidate for Hearing Restoration

WOBURN, Mass., April 9, 2019 – Frequency Therapeutics, a clinical-stage biotechnology company, today announced positive results from a Phase 1/2 safety trial to evaluate FX-322, an investigational drug candidate designed to facilitate hearing restoration. The trial assessed the safety of a single dose of FX-322 given by intratympanic administration in adult patients with stable sensorineural hearing loss (SSHL) who had a medical history consistent with either chronic noise exposure or idiopathic sudden sensorineural hearing loss. In the Phase 1/2 study, FX-322 was safe and well tolerated following a single intratympanic injection with no serious adverse events. In addition, improvements in hearing function, including audiometry and word scores, were observed in multiple FX-322 treated patients.

 

more details:

http://www.frequencytx.com/news-events/news-events-press-release-04-09-2019.php

https://www.fiercebiotech.com/biotech/frequency-shows-early-positive-results-for-small-molecule-hearing-loss-therapy

https://www.businesswire.com/news/home/20190409005363/en/Frequency-Therapeutics-Announces-Positive-Phase-12-Data